Valitor Expands Leadership Team with Appointment of Omkar Joshi, Ph.D. as Vice President of CMC
19 juil. 2023 16h00 HE
|
Valitor, Inc.
BERKELEY, Calif., July 19, 2023 (GLOBE NEWSWIRE) -- Valitor, a biotechnology company engineering better medicines to conquer drug limitations, today announced the appointment of Omkar Joshi,...
Valitor Presents Preclinical Data on its Long-acting Anti-VEGF Biologic in Development for Durable Treatment of Wet AMD at the Association for Research in Vision and Ophthalmology Annual Meeting
24 avr. 2023 18h00 HE
|
Valitor, Inc.
BERKELEY, Calif., April 24, 2023 (GLOBE NEWSWIRE) -- Valitor, a biotechnology company engineering better medicines to conquer drug limitations, today announced new data from VLTR-557, its...
Valitor to Present on the Potential for its Multivalent Polymer Technology to Expand the Therapeutic Index of Oncology Agents at the 2023 American Association for Cancer Research Annual Meeting
10 avr. 2023 08h00 HE
|
Valitor, Inc.
BERKELEY, Calif., April 10, 2023 (GLOBE NEWSWIRE) -- Valitor, a biotechnology company engineering better medicines to conquer drug limitations, today announced that data reviewing the therapeutic...
Valitor to Present at the Association for Research in Vision and Ophthalmology Annual Meeting
23 mars 2023 08h00 HE
|
Valitor, Inc.
BERKELEY, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Valitor, a biotechnology company engineering better medicines to conquer drug limitations, today announced that two abstracts have been accepted...
Valitor Announces Presentation on Novel Anti-VEGF Antibody Conjugate and Multivalent Polymer Technology Platform at Upcoming Ophthalmology Innovation Source (OIS) Summit
01 déc. 2022 16h00 HE
|
Valitor, Inc.
BERKELEY, Calif., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Valitor, a biotechnology company engineering better medicines to conquer drug limitations, today announced that its president and chief scientific...
Valitor Announces the Closing of its Series B Financing and Names Steven Lo as Chief Executive Officer
05 oct. 2022 08h00 HE
|
Valitor, Inc.
BERKELEY, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Valitor, a biotechnology company engineering better medicines to conquer drug limitations, today announced that it has closed a Series B...